{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:15:54Z","timestamp":1792624554893,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.05.035","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T11:21:01Z","timestamp":1559733661000},"page":"1679-1684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Challenges and opportunities for drug delivery to the posterior of the eye"],"prefix":"10.1016","volume":"24","author":[{"given":"Fernando J.","family":"Cabrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5445-5364","authenticated-orcid":false,"given":"Ghanashyam","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal S.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.05.035_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/510285","article-title":"Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering","volume":"2014","author":"Fern\u00e1ndez-Robredo","year":"2014","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/608390","article-title":"Present and possible therapies for age-related macular degeneration","volume":"2014","author":"Khan","year":"2014","journal-title":"ISRN Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/dom.12384","article-title":"New treatments for diabetic retinopathy","volume":"17","author":"Das","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.drudis.2019.05.035_bib0020","doi-asserted-by":"crossref","first-page":"93751","DOI":"10.1172\/jci.insight.93751","article-title":"Diabetic retinopathy: current understanding, mechanisms, and treatment strategies","volume":"2","author":"Duh","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2019.05.035_bib0025","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.biopha.2018.08.138","article-title":"A review on recent drug delivery systems for posterior segment of eye","volume":"107","author":"Nayak","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2019.05.035_bib0030","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.12688\/f1000research.8265.1","article-title":"Diabetic macular edema: it is more than just VEGF","volume":"5","author":"Singer","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.drudis.2019.05.035_bib0035","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.05.035_bib0040","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3928\/23258160-20170928-01","article-title":"Treatment burden in neovascular AMD: visual acuity outcomes are associated with anti-VEGF injection frequency","volume":"48","author":"Hussain","year":"2017","journal-title":"Ophthal. Surg. Lasers Imaging Retina"},{"key":"10.1016\/j.drudis.2019.05.035_bib0045","first-page":"75","article-title":"Rate of endophthalmitis after anti-VEGF intravitreal injection","volume":"2008","author":"Moshfeghi","year":"2008","journal-title":"Retin. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2018.06.022","article-title":"Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections","volume":"194","author":"Borkar","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0055","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.05.035_bib0060","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s11948-015-9705-6","article-title":"Defining nano, nanotechnology and nanomedicine: why should it matter?","volume":"22","author":"Satalkar","year":"2016","journal-title":"Sci. Eng. Ethics"},{"key":"10.1016\/j.drudis.2019.05.035_bib0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.apsb.2016.09.001","article-title":"Nanotechnology-based strategies for treatment of ocular disease","volume":"7","author":"Weng","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drudis.2019.05.035_bib0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2018.01.012","article-title":"Ocular translational science: a review of development steps and paths","volume":"126","author":"Mann","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.05.035_bib0075","first-page":"44","article-title":"Relevance of nanotechnology to retinal disease","volume":"14","author":"Chang","year":"2017","journal-title":"Retin. Phys."},{"key":"10.1016\/j.drudis.2019.05.035_bib0080","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijpharm.2017.07.065","article-title":"Non-invasive strategies for targeting the posterior segment of eye","volume":"530","author":"Madni","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2019.05.035_bib0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.19080\/JPCR.2018.05.555654","article-title":"Nano technological drug release approaches for the treatment of eye diseases: myth, reality or challenge?","volume":"5","author":"Formica","year":"2018","journal-title":"J. Pharmacol. Clin. Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0090","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3389\/fphar.2012.00188","article-title":"Ocular drug delivery: a clue from nanotechnology","volume":"3","author":"Bucolo","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0095","first-page":"48","article-title":"Topical drug delivery for posterior segment disease","volume":"2010","author":"Kiernan","year":"2010","journal-title":"Retin. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15171\/bi.2016.07","article-title":"Advanced drug delivery and targeting technologies for the ocular diseases","volume":"6","author":"Barar","year":"2016","journal-title":"BioImpacts"},{"key":"10.1016\/j.drudis.2019.05.035_bib0105","first-page":"60","article-title":"Mucoadhesive nanopolymers for posterior segment drug delivery","volume":"2011","author":"Sahoo","year":"2011","journal-title":"Retin. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.preteyeres.2010.08.002","article-title":"Applications of nanoparticles in ophthalmology","volume":"29","author":"Diebold","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of particle size of polymeric nanospheres on intravitreal kinetics","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0120","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.biomaterials.2012.01.030","article-title":"The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection","volume":"33","author":"Koo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.05.035_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biomaterials.2017.02.006","article-title":"Evaluation of polyesteramide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats","volume":"124","author":"Peters","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2019.05.035_bib0135","first-page":"675","article-title":"Intravitreal bioerudivel sustained-release preliminary report of its potential usefulnes for the treatment of diabetic macular edema","volume":"81","author":"Cardillo","year":"2006","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0140","first-page":"2698","article-title":"Phase I\/II study of intravitreal triamcinolone acetonide microspheres for treatment of diffuse diabetic macular edema unresponsive to conventional laser photocoagulation treatment","volume":"49","author":"Lavinsky","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.035_bib0145","first-page":"84","article-title":"Ocular drug delivery via micro-and nanoparticles","volume":"2014","author":"O\u2019Rourke","year":"2014","journal-title":"Retin. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0150","series-title":"Ocular Drug Delivery Technology","author":"Graybug Vision","year":"2019"},{"key":"10.1016\/j.drudis.2019.05.035_bib0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2014.09.030","article-title":"Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems","volume":"196","author":"Yasin","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.035_bib0160","series-title":"Verisome Technology Overview","author":"Eyepoint Pharmaceuticals","year":"2019"},{"key":"10.1016\/j.drudis.2019.05.035_bib0165","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jcrs.2018.07.015","article-title":"Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study","volume":"44","author":"Donnenfeld","year":"2018","journal-title":"J. Cataract Refract. Surg."},{"key":"10.1016\/j.drudis.2019.05.035_bib0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/jop.2015.0133","article-title":"Posterior segment drug delivery devices: current and novel therapies in development","volume":"32","author":"Bansal","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.05.035_bib0175","first-page":"56","article-title":"A long-term treatment option for AMD?","volume":"2018","author":"Regillo","year":"2018","journal-title":"Retin. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0180","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S79785","article-title":"A novel intravitreal fluocinolone acetonide implant (Iluvien\u00ae) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series","volume":"25","author":"Schmit-Eilenberger","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0185","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4155\/tde-2018-0006","article-title":"ILUVIEN\u00ae technology in the treatment of center-involving diabetic macular edema: a review of the literature","volume":"9","author":"Habib","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.drudis.2019.05.035_bib0190","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3928\/23258160-20181101-02","article-title":"Update on emerging steroid-based local treatments for noninfectious uveitis","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthal. Surg. Lasers Imaging Retina"},{"key":"10.1016\/j.drudis.2019.05.035_bib0195","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/nnm-2016-0379","article-title":"Drug delivery to the eye: what benefits do nanocarriers offer?","volume":"12","author":"Joseph","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.035_bib0200","first-page":"46","article-title":"The port delivery system with ranibizumab","volume":"16","author":"Pieramici","year":"2019","journal-title":"Retin. Phys."},{"key":"10.1016\/j.drudis.2019.05.035_bib0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0210","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.2147\/IJN.S162306","article-title":"Montmorillonite\/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma","volume":"13","author":"Li","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2019.05.035_bib0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5301\/EJO.2010.6051","article-title":"Drug delivery to the posterior segment of the eye","volume":"21","author":"Fischer","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0220","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0225","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.nano.2017.02.007","article-title":"Nano-ophthalmology: applications and considerations","volume":"13","author":"Kamaleddin","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.035_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/164_2016_32","article-title":"Ocular pharmacokinetics","volume":"242","author":"Durairaj","year":"2016","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0235","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0240","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.exer.2015.10.009","article-title":"Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye","volume":"145","author":"Chastain","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0245","first-page":"50","article-title":"Topical drug delivery for retinal disease management","volume":"2018","author":"Boyer","year":"2018","journal-title":"Retin. Today"},{"key":"10.1016\/j.drudis.2019.05.035_bib0250","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaophthalmol.2016.0045","article-title":"Topical dorzolamide-timolol with intravitreous anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"134","author":"Sridhar","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0255","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5301\/ejo.5000888","article-title":"Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study","volume":"27","author":"Pinna","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0260","first-page":"2","article-title":"Recent advances in topical therapeutics for vitreoretinal diseases","volume":"8","author":"Gibson","year":"2015","journal-title":"US Ophthalmic Rev."},{"key":"10.1016\/j.drudis.2019.05.035_bib0265","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jddst.2018.04.007","article-title":"Topical drug delivery to the posterior segment of the eye: dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits","volume":"45","author":"Johannsdottir","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0270","first-page":"394","article-title":"Feasibility of drug delivery to the eye\u2019s posterior segment by topical instillation of PLGA nanoparticles","volume":"12","author":"Tahara","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.05.035_bib0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejps.2014.04.018","article-title":"Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes","volume":"62","author":"Lajunen","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.05.035_bib0280","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.colsurfb.2011.06.025","article-title":"Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye","volume":"88","author":"Ara\u00fajo","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.drudis.2019.05.035_bib0285","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.actbio.2014.11.032","article-title":"Electrospun nitric oxide releasing bandage with enhanced wound healing","volume":"13","author":"Lowe","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drudis.2019.05.035_bib0290","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.nano.2016.04.006","article-title":"Mucus-penetrating nanoparticles made with \u2018mucoadhesive\u2019 poly(vinyl alcohol)","volume":"12","author":"Popov","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.035_bib0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.4.3.11","article-title":"Topical ocular drug delivery to the back of the eye by mucus-penetrating particles","volume":"4","author":"Schopf","year":"2016","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.drudis.2019.05.035_bib0300","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1167\/iovs.16-20072","article-title":"Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides","volume":"58","author":"de Cogan","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.035_bib0305","first-page":"1439","article-title":"Topical treatment for AMD: non-invasive delivery and efficacy of ranibizumab and bevacizumab in rabbit and porcine eyes","volume":"59","author":"De Cogan","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.035_bib0310","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/02713683.2015.1050738","article-title":"Hydrogel ring for topical drug delivery to the ocular posterior segment","volume":"41","author":"Shikamura","year":"2016","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0315","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11095-018-2519-x","article-title":"Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation","volume":"35","author":"Rodrigues","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.05.035_bib0320","article-title":"Use of rabbit eyes in pharmacokinetic studies of intraocular drugs","volume":"113","author":"Ahn","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.drudis.2019.05.035_bib0325","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.nano.2015.12.376","article-title":"Challenges of clinical translation in nanomedicine: a qualitative study","volume":"12","author":"Satalkar","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.035_bib0330","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2017.07.030","article-title":"The drug delivery field at the inflection point: time to fight its way out of the egg","volume":"267","author":"Park","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.035_bib0335","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: principles, properties, and regulatory issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front. Chem."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618305191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618305191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:42:51Z","timestamp":1761223371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618305191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618305191"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.035","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities for drug delivery to the posterior of the eye","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}